Oral chronic graft-versus-host disease

Haverman, Thijs; Raber-Durlacher, Judith E.; Raghoebar, Iva I.; Rademacher, W. M. H.; Rozema, F.R.; Hazenberg, Mette D.; Epstein, Joel B.; Treister, Nathaniel S.

doi:10.1016/j.adaj.2020.08.001

Cited by 21 publications

(10 citation statements)

References 54 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Chronic GVHD is a complication of allo-HSCT ( 4 , 7 , 11 ). Oral cGVHD causes significant pain and discomfort, dysfunction, and limits oral intake ( 5 , 15 ). The most common symptom of oral cGVHD patients is sensitivity to spicy, acidic, and strongly flavored food ( 4 , 16 ).…”

Section: Discussionmentioning

confidence: 99%

Therapeutic response of oral chronic graft-versus-host disease to topical corticosteroids according to the 2014 National Institutes of Health (USA) consensus criteria

Siripornkitti,

Pengpis,

Chanswangphuwana

et al. 2024

Med Oral

View full text Add to dashboard Cite

Background Chronic graft-versus-host-disease (cGVHD) is a major cause of morbidity and mortality after allogeneic hematopoietic stem cell transplantation. The oral cavity is one of the most frequently affected anatomic sites and is affected in 70% of all patients who develop cGVHD. The objective of this study was to determine the therapeutic response to topical corticosteroids and clinical outcome of patients with oral cGVHD using the 2014 NIH consensus criteria. Material and Methods The oral manifestations of cGVHD were collected at the first and the follow-up (FU) visits after the therapeutic treatment of oral GVHD. The FU intervals were: FU0, first visit; FU1, 0-1 month; FU2, 1-3 months; FU3, 3-6 months; FU4, 6-9 months; and FU5, 9-12 months. The oral cGVHD activity was assessed using the NIH modification of the Schubert Oral Mucosa Rating Scale (OMRS) and Thongprasom sign score. The functional impact was assessed by the organ-specific severity score. Results Fourteen patients (93.3%) at FU0 were being treated with at least one form of systemic immunosuppressive therapy, i.e., prednisolone, cyclosporin, and tacrolimus. The OMRS was reduced between FU0 and FU3 ( p < 0.001), FU0 and FU4 ( p < 0.001), and FU0 and FU5 ( p = 0.004). The organ-specific severity scores were also reduced between FU0 and FU4 ( p = 0.016), and FU0 and FU5 ( p = 0.001). There was no significant difference in the highest Thongprasom sign score between all follow-up intervals (FU0-FU5) ( p = 0.201). One patient (6.7%) at FU4 and three patients (20.0%) at FU5 did not receive topical corticosteroid therapy for oral cGVHD. Conclusions The oral cGVHD lesions and functional impacts improved within 6 months and 9 months, respectively. However, most of the patients required topical corticosteroid therapy for more than 1 year to control their symptoms and lesions. Key words: Oral chronic graft-versus-host disease, 2014 National Institutes of Health consensus criteria, Hematopoietic cell transplantation, therapeutic response, topical corticosteroid.

show abstract

Section: Discussionmentioning

confidence: 99%

Therapeutic response of oral chronic graft-versus-host disease to topical corticosteroids according to the 2014 National Institutes of Health (USA) consensus criteria

Siripornkitti,

Pengpis,

Chanswangphuwana

et al. 2024

Med Oral

View full text Add to dashboard Cite

show abstract

“…Haverman et al emphasized the importance of allo-HCT patients consulting oral health practitioners for early identification of oral conditions arising from their medical status. In their research, the authors investigated oral outcomes following cellular therapy aimed at treating diverse hematological diseases, both malignant and nonmalignant [ 1 ]. They observed an increased likelihood of developing oral features, such as superficial mucoceles, trismus, lichenoid lesions, and heightened sensitivity of certain mouth regions to various foods [ 61 ].…”

Section: Oral Biomarkers For Gvhdmentioning

confidence: 99%

“…AlloHCT is one of the most effective and frequently performed treatment strategies used for conditions such as hematological malignancies, hemoglobinopathies, and others [ 1 ]. The higher life expectancy ratios also indicate higher risks for post-transplantation complications, including graft-versus-host disease [ 2 ].…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Graft-Versus-Host Disease: Can Biomarkers Assist in Differential Diagnosis, Prognosis, and Therapeutic Strategy?

Alexoudi,

Gavriilaki,

Cheva

et al. 2024

Pharmaceuticals

View full text Add to dashboard Cite

A crucial complication after allogeneic hematopoietic cell transplantation (alloHCT), namely, acute graft-versus-host disease (aGVHD), occurs in about 50% of transplant recipients, leading to high morbidity and mortality. Thus far, the diagnosis of GVHD has been mainly established through clinical features and histologic or laboratory evidence of periductal lymphocyte infiltration, fibroplasia, and mixed lymphocytic and plasmocytic inflammation. Intensive research is focused on identifying biomarkers for the early diagnosis, prediction of disease, response to treatment, prognosis, and risk stratification of patients. The serum biomolecules that have been investigated are reported and summarized. Moreover, oral tissue involvement in GVHD is described, and other biomarkers that have been proposed, such as saliva, are analyzed. Future research is highlighted as a necessity in order for these biomarkers to be validated and quantified for use in clinical practice.

show abstract

“…Oral cavity is a main organ involved in cGVHD, affecting 45-83% of cGVHD patients [3]. Covering lichen planus-like changes, erythema, ulceration, mucoceles, etc., the clinical presentation of oral cGVHD is diverse and can in uence any site in oral cavity such as oral mucosa, salivary gland and periodontium [4,5]. Lichen planus-like changes, characterized by hyperkeratotic white lines and lacy-appearing lesions on the oral mucosa, serve as the diagnostic feature of oral cGVHD among oral manifestations [6].…”

Section: Introductionmentioning

confidence: 99%

miRNA-769-5p and Smad2 Differential Expression in Patients with or without Oral cGVHD

Yong

Zhou

Jiang

et al. 2023

Preprint

View full text Add to dashboard Cite

Background: Oral chronic graft versus host disease (Oral cGVHD) affects the life quality of patient. But its pathogenesis is still unclear. MicroRNA (miRNA) involves in numerous pathologic and physiologic processes. Objective: To preliminarily observe the change of miRNAs in oral cGVHD. Methods: Peripheral venous blood was taken from 8 cases of oral cGVHD, 8 cases without oral cGVHD, and 8 cases of healthy control group to construct the miRNAs library by Illumina Hiseq 2500 platform. The expression of miRNA-769-5p was detected by qRT-PCR in each group with subjects adding to 15. The interactions between miRNA-769-5p and Smad2 mRNA was verified by dual-luciferase assay. qRT-PCR and ELISA was used to detect the mRNA and protein level of Smad2 in peripheral blood respectively. Results: All three groups expressed 518 miRNAs and 191 miRNAs showed significantly different expression. The expression of miRNA-769-5p was the higher in non-oral cGVHD patients than that in oral cGVHD patients, and were of certain value in the diagnosis of oral cGVHD. The levels of Smad2 mRNA and protein were higher in the oral cGVHD group than those without oral cGVHD. As a target of miRNA-769-5p, Smad2 mRNA was negatively related to it. Conclusion: Differential expression of miRNAs, especially miRNA-769-5p may be involved in oral cGVHD. High expression of circulating Smad2 may be associated with the oral cGVHD, which might be regulated by miRNA-769-5p.

show abstract

Oral chronic graft-versus-host disease

Cited by 21 publications

References 54 publications

Therapeutic response of oral chronic graft-versus-host disease to topical corticosteroids according to the 2014 National Institutes of Health (USA) consensus criteria

Therapeutic response of oral chronic graft-versus-host disease to topical corticosteroids according to the 2014 National Institutes of Health (USA) consensus criteria

Graft-Versus-Host Disease: Can Biomarkers Assist in Differential Diagnosis, Prognosis, and Therapeutic Strategy?

miRNA-769-5p and Smad2 Differential Expression in Patients with or without Oral cGVHD

Contact Info

Product

Resources

About